Clinical pharmacology of antihypertensive therapy

Seminars in Nephrology

Volumn 25, Issue 4, 2005, Pages 215-226

  Taylor, Addison A ^a   Pool, James L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha 1 adrenergic blockers; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Antihypertensive drugs; Beta blockers; Calcium channel antagonists; Combination therapy; Diuretics

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; MINOXIDIL; NIFEDIPINE; OLMESARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD PRESSURE REGULATION; CALVARIA; CARDIOVASCULAR DISEASE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; ELECTROLYTE DISTURBANCE; FETUS DISEASE; FLUSHING; GLOMERULONEPHRITIS; HEADACHE; HEALTH SURVEY; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPLASIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; LIMB DEFECT; LOW DRUG DOSE; LUNG HYPOPLASIA; LUPUS ERYTHEMATOSUS; METABOLIC DISORDER; MONOTHERAPY; MORBIDITY; MORTALITY; OLIGOHYDRAMNIOS; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PHYSICIAN; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; UNITED STATES;

EID: 22544461052     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2005.02.006     Document Type: Article

References (91)

1. A. Chobanian, G.L. Bakris, H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 report JAMA 289 2003 2560 2572
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
3. W.C. Cushman, C.E. Ford, J.A. Cutler Success and predictors of blood pressure control in diverse North American settings The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 4 2002 393 404
4. P.E. De Jong, G. Navis, Z.D. de Renoprotective therapy Titration against urinary protein excretion Lancet 354 1999 352 353
5. M.S. Weinberg, N. Kaperonis, G.L. Bakris How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 5 2003 418 425
6. J.H. Morledge, B. Ettinger, J. Aranda Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone J Am Geriatr Soc 34 1986 199 206
7. L.V. Franse, M. Pahor, B.M. Di Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program Hypertension 35 2000 1025 1030
8. B.M. Psaty, N.L. Smith, D.S. Siscovick Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis JAMA 277 1997 739 745
9. L.V. Franse, M. Pahor, M. Di Bari Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program Hypertension 35 2000 1025 1030
10. J.M. Flack, E. Saunders, A. Gradman Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension Clin Ther 23 2001 1193 1208
11. B.J. Materson, D.J. Reda, W.C. Cushman The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo N Engl J Med 328 1993 914 921
12. B.J. Materson, D.J. Reda, W.C. Cushman Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data Am J Hypertens 8 1995 189 192
13. B.J. Materson, D.J. Reda, R.A. Preston Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug Arch Intern Med 155 1995 1757 1762
14. R.C. Tarazi, H.P. Dustan, E.D. Frohlich Long-term thiazide therapy in essential hypertension Evidence for persistent alteration in plasma volume and renin activity Circulation 41 1970 709 717
15. B.M. Psaty, T. Lumley, C.D. Furberg Health outcomes associated with various antihypertensive therapies used as first-line agents A network meta-analysis JAMA 289 2003 2534 2544
16. D.G. Vidt The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure Cleve Clin J Med 70 2003 263 269
17. T. Pollare, H. Lithell, C. Berne A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension N Engl J Med 321 1989 868 873
18. H. Cardinal, A.A. Monfared, M. Dorais A comparison between persistence to therapy in ALLHAT and in everyday clinical practice A generalizability issue Can J Cardiol 20 2004 417 421
19. L.H. Lindholm, M. Persson, P. Alaupovic Metabolic outcome during 1 year in newly detected hypertensives Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) J Hypertens 21 2003 1563 1574
20. P. Verdecchia, G. Reboldi, F. Angeli Adverse prognostic significance of new diabetes in treated hypertensive subjects Hypertension 43 2004 963 969
21. D.A. Sica Current concepts of pharmacotherapy in hypertension: Diuretic-related side effects: Development and treatment J Clin Hypertens (Greenwich) 6 2004 532 540
22. B.L. Carter, M.E. Ernst, J.D. Cohen Hydrochlorothiazide versus chlorthalidone Evidence supporting their interchangeability Hypertension 43 2004 4 9
23. J.B. Soriano, A.W. Hoes, L. Meems Increased survival with beta-blockers Importance of ancillary properties Prog Cardiovasc Dis 39 1997 445 456
24. N. Freemantle, J. Cleland, P. Young Beta blockade after myocardial infarction Systematic review and meta regression analysis BMJ 318 1999 1730 1737
25. L.M. Brewster, G.A. van Montfrans, J. Kleijnen Systematic review Antihypertensive drug therapy in black patients Ann Intern Med 141 2004 614 627
26. C.W. Yancy, S. Laskar, E. Eichhorn The use of beta-adrenergic receptor antagonists in the treatment of African Americans with heart failure Congest Heart Fail 10 2004 34 37
27. E. Grossman, F.H. Messerli Why beta-blockers are not cardioprotective in elderly patients with hypertension Curr Cardiol Rep 4 2002 468 473
28. F.H. Messerli, E. Grossman, U. Goldbourt Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?. A systematic review JAMA 279 1998 1903 1907
29. M. Cazzola, P. Noschese, G. D'Amato The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction Chest 121 2002 230 241
30. S.R. Salpeter, T.M. Ormiston, E.E. Salpeter Cardioselective {beta}-blockers in patients with reactive airway disease A meta-analysis Ann Intern Med 137 2002 715 725
31. T.M. Ormiston, S.R. Salpeter Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease Moving from myth to evidence-based practice Heart Fail Monit 4 2003 45 54
32. B. Carlberg, O. Samuelsson, L.H. Lindholm Atenolol in hypertension Is it a wise choice? Lancet 364 2004 1684 1689
33. J.R. Kizer, B. Dahlof, S.E. Kjeldsen Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol The Losartan Intervention For Endpoint reduction in hypertension study Hypertension 45 2005 46 52
34. G.H. Hockerman, B.Z. Peterson, A.B. Johnson Molecular determinants of drug binding and action on L-type calcium channels Ann Rev Pharmacol Toxicol 37 1997 361 396
35. J.J. Saseen, B.L. Carter, T.E. Brown Comparison of nifedipine alone and with diltiazem or verapamil in hypertension Hypertension 28 1996 109 114
36. P.H. Held, S. Yusuf, C.D. Furberg Calcium channel blockers in acute myocardial infarction and unstable angina An overview BMJ 299 1989 1187 1192
37. X. Zhang, T.H. Hintze Amlodipine releases nitric oxide from canine coronary microvessels An unexpected mechanism of action of a calcium channel-blocking agent Circulation 97 1998 576 580
38. X.P. Zhang, K.E. Loke, S. Mital Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine J Cardiovasc Pharmacol 39 2002 208 214
39. X. Zhang, X. Xu, A. Nasjletti Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels J Cardiovasc Pharmacol 35 2000 195 202
40. D.R. Abernethy, J.B. Schwartz Calcium-antagonist drugs N Engl J Med 341 1999 1447 1457
41. W.C. Cushman Are there benefits to specific antihypertensive drug therapy? Am J Hypertens 16 2003 31S 35S
42. H. Cai, D.G. Harrison Endothelial dysfunction in cardiovascular diseases The role of oxidant stress Circ Res 87 2000 840 844
43. J.D. Irvin, J.M. Viau Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril Am J Med 81 1986 46 50
44. V.J. Dzau, K. Bernstein, D. Celermajer Pathophysiologic and therapeutic importance of tissue ACE A consensus report Cardiovasc Drugs Ther 16 2002 149 160
45. W.J. Elliott Optimizing medication adherence in older persons with hypertension Int Urol Nephrol 35 2003 557 562
46. G.L. Bakris, M.R. Weir Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine Is this a cause for concern? Arch Intern Med 160 2000 685 693
47. K.C. Ferdinand Recommendations for the management of special populations Racial and ethnic populations Am J Hypertens 16 2003 50S 54S
48. Z.H. Israili, W.D. Hall Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology Ann Intern Med 117 1992 234 242
49. A. Trifilieff, A. Da Silva, J.P. Gies Kinins and respiratory tract diseases Eur Respir J 6 1993 567 587
50. L.P. Boulet, J. Milot, N. Lampron Pulmonary function and airway responsiveness during long-term therapy with captopril JAMA 261 1989 413 416
51. C.R. Gibbs, G.Y. Lip, D.G. Beevers Angioedema due to ACE inhibitors Increased risk in patients of African origin Br J Clin Pharmacol 48 1999 861 865
52. N.J. Brown, W.A. Ray, M. Snowden Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema Clin Pharmacol Ther 60 1996 8 13
53. K.W. Gregory, R.C. Davis Images in clinical medicine. Angioedema of the intestine N Engl J Med 334 1996 1641
54. P.G. Pryde, A.B. Sedman, C.E. Nugent Angiotensin-converting enzyme inhibitor fetopathy J Am Soc Nephrol 3 1993 1575 1582
55. M.A. Lambot, D. Vermeylen, J.C. Noel Angiotensin-II-receptor inhibitors in pregnancy Lancet 357 2001 1619 1620
56. W.B. White, J. Kent, A. Taylor Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors Hypertension 39 2002 929 934
57. M. Izhar, T. Alausa, A. Folker Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics Hypertension 43 2004 573 577
58. Z.H. Israili Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension J Hum Hypertens 14 suppl 1 2000 S73 S86
59. S. Oparil Newly emerging pharmacologic differences in angiotensin II receptor blockers Am J Hypertens 13 2000 18S 24S
60. J. Stangier, C.A. Su, M.G. Hendriks The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers J Clin Pharmacol 40 2000 1373 1379
61. S.F. Gardner, A.M. Franks Olmesartan medoxomil The seventh angiotensin receptor antagonist Ann Pharmacother 37 2003 99 105
62. D.A. Sica, T.W. Gehr The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease J Renin Angiotensin Aldosterone Syst 3 2002 247 254
63. J.L. Pool Doxazosin A new approach to hypertension and benign prostatic hyperplasia Br J Clin Pract 50 1996 154 163
64. J.L. Pool, A.A. Taylor, E.B. Nelson Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension Am J Med 87 1989 57S 61S
65. G.T. McInnes The value of alpha-blockers in the management of hypertension A practical view J Hum Hypertens 5 1991 313 316
66. D.A. Sica Minoxidil An underused vasodilator for resistant or severe hypertension J Clin Hypertens (Greenwich) 6 2004 283 287
67. A.L. Taylor, S. Ziesche, C. Yancy Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med 351 2004 2049 2057
68. P. Carson, S. Ziesche, G. Johnson Vasodilator-Heart Failure Trial Study Group Racial differences in response to therapy for heart failure analysis of the vasodilator-heart failure trials J Card Fail 5 1999 178 187
69. P.A. Reece, R. Zacest Hydralazine F.H. Messerli Cardiovascular Drug Therapy 1990 WB Saunders Philadelphia 834 848
70. D.A. Sica, T.W. Gehr Direct vasodilators and their role in hypertension management Minoxidil J Clin Hypertens (Greenwich) 3 2001 110 114
71. H. Ausubel, M.L. Levine Treatment of hypertension with Ser-Ap-Es Curr Ther Res Clin Exp 9 1967 29 35
72. D.C. Ellershaw, A.M. Gurney Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery Br J Pharmacol 134 2001 621 631
73. G.L. Schwartz, S.T. Turner Pharmacogenetics of antihypertensive drug responses Am J Pharmacogenomics 4 2004 151 160
74. K. Oelke, B. Richardson Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression Int Rev Immunol 23 2004 315 331
75. H.A. Cameron, L.E. Ramsay The lupus syndrome induced by hydralazine A common complication with low dose treatment BMJ 289 1984 410 412
76. V.M. Campese Minoxidil F.H. Messerli Cardiovascular Drug Therapy 1990 WB Saunders Philadelphia 849 860
77. J.L. Parish, M.A. Hughes, G.W. Cherry The effect of minoxidil analogues and metabolites on the contraction of collagen lattices by human skin fibroblasts Br J Plast Surg 48 1995 154 160
78. O.B. Holland, K.L. von, W.B. Campbell Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients Hypertension 5 1983 235 239
79. S. Julius, M. Alderman, G. Beevers Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy The life study J Am Coll Cardiol 43 2004 1047 1055
80. D.N. Juurlink, M.M. Mamdani, D.S. Lee Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
81. K.A. Jamerson, O. Nwose, L. Jean-Louis Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension Am J Hypertens 17 2004 495 501
82. J.M. Neutel, D.H.G. Smith Effects of fixed, low-dose combination amlodipine/benazepril therapy vs component monotherapy on systolic blood pressure Results of the SELECT (systolic evaluation of Lotrel efficacy and comparative therapies) trial Am J Hypertens 16 2003 196A
83. J.M. Neutel, D.H.G. Smith, M.A. Weber Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass Am J Hypertens 17 2004 37 42
84. L.Y. Agodoa, L. Appel, G.L. Bakris Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis A randomized controlled trial JAMA 285 2001 2719 2728
85. J.T. Wright Jr, G.L. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease Results from the AASK trial JAMA 288 2002 2421 2431
86. G.L. Bakris, M.R. Weir, V. Dequattro Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy Kidney Int 54 1998 1283 1289
87. J.P. Lash, G.L. Bakris Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy Nephrol Dial Transplant 10 suppl 9 1995 56 62
88. R. Boero, C. Rollino, C. Massara The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study Am J Kidney Dis 42 2003 67 75
89. F.H. Messerli Vasodilatory edema A common side effect of antihypertensive therapy Curr Cardiol Rep 4 2002 479 482
90. M.K. Nishizaka, M.A. Zaman, D.A. Calhoun Efficacy of low-dose spironolactone in subjects with resistant hypertension Am J Hypertens 16 2003 925 930
91. Physician's Desk Reference 2005 Thompson PDR Montvale, NJ